Lung Cancer Trial Results
- Crizotinib Improves Progression-Free Survival in Some Patients with Advanced Lung Cancer (Updated)
(Updated: 12/04/2014) - Results from an international phase III trial show that crizotinib (Xalkori®) substantially extends progression-free survival in previously treated patients with advanced lung cancer whose tumors have a specific genetic mutation.
- Expanding the Playing Field: Immune-Based Therapy Shows Potential for Lung, Other Cancers
(Posted: 06/15/2012) - Results from two early-phase clinical trials presented at the 2012 American Society of Clinical Oncology annual meeting provide further evidence that priming the immune system to attack tumors has potential as a treatment for certain cancers.
- Annual Screening with Chest X-Ray Does Not Reduce Lung Cancer Deaths
(Posted: 12/02/2011) - Annual screening for lung cancer using a standard chest x-ray does not reduce the risk of dying from lung cancer when compared with no annual screening, according to findings from the NCI-led Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial.
- Chemotherapy Combination Improves Survival in Elderly Lung Cancer Patients
(Posted: 06/23/2010, Updated: 09/06/2011) - Survival can be improved in older patients with advanced non-small cell lung cancer (NSCLC) with the use of two chemotherapy drugs as opposed to a single agent.
- NIH-funded study shows 20 percent reduction in lung cancer mortality with low-dose CT compared to chest X-ray:
(Posted: 06/29/2011) - Scientists have found a 20 percent reduction in deaths from lung cancer among current or former heavy smokers who were screened with low-dose helical computed tomography (CT) versus those screened by chest X-ray.